Cargando…

Short term visual and structural outcomes of anti-vascular endothelial growth factor (anti-VEGF) treatment delay during the first COVID-19 wave: A pilot study

Regularly scheduled intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections are essential to maintaining and/or improving many ocular conditions including: neovascular age-related macular degeneration (nAMD), diabetic retinopathy, and retinal vein occlusions with macular edema (R...

Descripción completa

Detalles Bibliográficos
Autores principales:	Naravane, Ameay V., Mundae, Rusdeep, Zhou, Yujia, Santilli, Christopher, van Kuijk, Frederik J. G. M., Nazari, Hossein, Yamanuha, Justin, Emerson, Geoffrey G., Koozekanani, Dara D., Montezuma, Sandra R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7888661/ https://www.ncbi.nlm.nih.gov/pubmed/33596257 http://dx.doi.org/10.1371/journal.pone.0247161

Ejemplares similares

The Effect of Scleral Buckling Surgery on Choroidal Thickness Measured by Enhanced Depth Optical Coherence Tomography: A Cross-Sectional Study
por: Montezuma, Sandra R., et al.
Publicado: (2016)

Sustained Control of Serpiginous Choroiditis with the Fluocinolone Acetonide 0.18 mg Intravitreal Implant
por: Siddiqui, Yousuf, et al.
Publicado: (2022)

Comparing fundus autofluorescence and infrared imaging findings of peripheral retinoschisis, schisis detachment, and retinal detachment
por: Huang, Natalie T., et al.
Publicado: (2020)

Retinal Findings and Cardiovascular Risk: Prognostic Conditions, Novel Biomarkers, and Emerging Image Analysis Techniques
por: Colcombe, Joseph, et al.
Publicado: (2023)

Acute anterior uveitis after topical interferon for conjunctival intraepithelial neoplasia (CIN)
por: Naravane, Ameay V., et al.
Publicado: (2021)

Association of Optic Nerve Head Drusen with Best Vitelliform Macular Dystrophy: A Case Series
por: White, Robert J., et al.
Publicado: (2018)

Aggressive Posterior Retinopathy of Prematurity: Long-Term Outcomes Following Intravitreal Bevacizumab
por: Naravane, Ameay V., et al.
Publicado: (2022)

Strategies for Improving Patient Comfort During Intravitreal Injections: Results from a Survey-Based Study
por: Gomez, Jessica, et al.
Publicado: (2016)

Vitreoretinopathy-Associated Pediatric Retinal Detachment Treatment Outcomes: IRIS® Registry (Intelligent Research in Sight) Analysis
por: Belin, Peter J., et al.
Publicado: (2023)

COVID-19 Vaccination Hesitancy and Its Association With Altered Presentation of Primary Rhegmatogenous Retinal Detachment
por: Mundae, Rusdeep, et al.
Publicado: (2022)

Fully-automated segmentation of fluid regions in exudative age-related macular degeneration subjects: Kernel graph cut in neutrosophic domain
por: Rashno, Abdolreza, et al.
Publicado: (2017)

Trends in the Clinical Presentation of Primary Rhegmatogenous Retinal Detachments During the First Year of the COVID-19 Pandemic
por: Mundae, Rusdeep, et al.
Publicado: (2022)

Anti-VEGF and Beyond
por: Bertelmann, T., et al.
Publicado: (2017)

The era of anti-vascular endothelial growth factor (VEGF) drugs in ophthalmology, VEGF and anti-VEGF therapy
por: Pożarowska, Dorota, et al.
Publicado: (2016)

Pazopanib and anti-VEGF therapy
por: Drabkin, Harry A
Publicado: (2010)

Anti-VEGF Treatment Strategies for Wet AMD
por: Kovach, Jaclyn L., et al.
Publicado: (2012)

The remote effects of intravitreal anti-VEGF therapy
por: Balta, F, et al.
Publicado: (2016)

Delayed Intravitreal Anti-VEGF Therapy for Patients During the COVID-19 Lockdown: An Ethical Endeavor
por: Elfalah, Mutasem, et al.
Publicado: (2021)

Aflibercept (VEGF Trap-eye): the newest anti-VEGF drug
por: Stewart, Michael W
Publicado: (2012)

Anti-VEGF Therapy and the Retina: An Update
por: Tah, Vikas, et al.
Publicado: (2015)

Anti-angiogenic alternatives to VEGF blockade
por: Khan, Kabir A., et al.
Publicado: (2015)

Anti-VEGF drugs in the prevention of blindness
por: Yorston, David
Publicado: (2014)

Anti-VEGF drugs: evidence for effectiveness
por: Evans, Jennifer, et al.
Publicado: (2014)

Tumor refractoriness to anti-VEGF therapy
por: Ribatti, Domenico
Publicado: (2016)

Brolucizumab—another anti-VEGF or beyond
por: Sharma, Ashish, et al.
Publicado: (2020)

Tuberculosis pathophysiology and anti-VEGF intervention
por: Maison, David P.
Publicado: (2022)

Future of anti-VEGF: biosimilars and biobetters
por: Kapur, Monika, et al.
Publicado: (2022)

Resistance to Anti-Angiogenic Therapy in Cancer—Alterations to Anti-VEGF Pathway
por: Itatani, Yoshiro, et al.
Publicado: (2018)

Effects of the COVID-19 pandemic on neovascular age-related macular degeneration and response to delayed Anti-VEGF treatment
por: Yeter, D.Y., et al.
Publicado: (2021)

Anti-VEGF for the Management of Diabetic Macular Edema
por: Stefanini, Francisco Rosa, et al.
Publicado: (2014)

Changing paradigms of anti-VEGF in the Indian scenario
por: Shanmugam, P Mahesh
Publicado: (2014)

Anti-VEGF Cancer Therapy in Nephrology Practice
por: Izzedine, Hassan
Publicado: (2014)

Anti-VEGF Agents and Glaucoma Filtering Surgery
por: Daneshvar, Ramin
Publicado: (2013)

Book Review: Anti-VEGF Use in Ophthalmology
por: Vora, Robin A.
Publicado: (2017)

Screening and Improvement of an Anti-VEGF DNA Aptamer
por: Nonaka, Yoshihiko, et al.
Publicado: (2010)

Use of Anti-VEGF Agents in Glaucoma Surgery
por: Slabaugh, Mark, et al.
Publicado: (2017)

Leukostasis retinopathy treated with Anti-VEGF therapy
por: Shakibai, Nasim, et al.
Publicado: (2020)

Issues with Intravitreal Administration of Anti-VEGF Drugs
por: Schargus, Marc, et al.
Publicado: (2020)

Inflammatory Complications of Intravitreal Anti-VEGF Injections
por: Cox, Jacob T., et al.
Publicado: (2021)

Biomarkers as Predictive Factors of Anti-VEGF Response
por: Bobadilla, Miriam, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0rbucgetols56nd18piuaf0h57